Acute Kidney Injury in Hospitalized Patients Infected with COVID-19 from Wuhan, China: A Retrospective Study
Table 2
Laboratory tests of patients infected with SARS-CoV-2 ().
Laboratory tests
Patients with AKI
Patients without AKI
value
Leucocytes (×109 per L; normal range 3.5–9.5)
Mean
9.32 (4.85-16.31)
5.03 (3.93-6.28)
<0.001
Normal
14 (38.89%)
352 (77.19%)
Increased
17 (47.22%)
27 (5.92%)
Decreased
5 (13.89%)
77 (16.89%)
Lymphocytes (×109 per L; normal range 1.1–3.2)
Mean
0.59 (0.36-1.23)
1.11 (0.8-1.48)
<0.001
Normal
8 (22.22%)
225 (49.34%)
Increased
1 (2.78%)
5 (1.10%)
Decreased
27 (75%)
226 (49.56%)
Lymphocyte percentage (20-50%)
Mean
6.6 (3.38-23.8)
24.15 (16.7-32.4)
<0.001
Normal
9 (25%)
289 (63.40%)
Increased
2 (5.56%)
4 (0.88%)
Decreased
25 (69.44%)
163 (35.75%)
Neutrophils (×109 per L; normal range 1.8–6.3)
Mean
7.64 (3.61-15.24)
3.2 (2.31-4.47)
<0.001
Normal
15 (41.67%)
354 (77.63%)
Increased
18 (50%)
47 (10.31%)
Decreased
3 (8.33%)
55 (12.06%)
Neutrophil percentage (40-75%)
Mean
87.95 (67.83-92.55)
65.6 (56.93-74.28)
<0.001
Normal
10 (27.78%)
337 (73.90%)
Increased
24 (66.67%)
111 (24.34%)
Decreased
2 (5.56%)
8 (1.75%)
PCT (ng/L)
Mean
0.29 (0.07-1.66)
0.04 (0.02-0.07)
<0.001
<0.5
26 (72.22%)
440 (96.49%)
0.5-2
5 (13.89%)
11 (2.41%)
2-10
5 (13.89%)
4 (0.88%)
≥10
0.00
1 (0.22%)
CRP (mg/L)
Mean
45.97 (15.98-107.73)
15.9 (3.61-49.23)
<0.001
0-10
8 (22.22%)
182 (39.91%)
10-25
5 (13.89%)
85 (18.64%)
25-50
7 (19.44%)
77 (16.89%)
50-100
6 (16.67%)
78 (17.11%)
≥100
10 (27.78%)
34 (7.46%)
Data are median (IQR), or (%), where is the total number of patients with available data. values comparing patients with AKI and without AKI are from chi-square or Mann–Whitney test. SARS-CoV-2 = 2019 novel coronavirus; AKI = acute kidney injury; PCT = procalcitonin; CRP = C-reactive protein.
